Canadian researchers testing SARS vaccine in China

Kondro, Wayne
January 2004
CMAJ: Canadian Medical Association Journal;1/20/2004, Vol. 170 Issue 2, p183
Academic Journal
Reports on the animal trials of potential vaccines for SARS, being conducted by the SARS Accelerated Vaccine Initiative, an international consortium led by the University of British Columbia Centre for Disease Control, as of January 2004. Reasons for conducting such trials in China; Concerns over China's implementation of the standards for medical research of the World Medication Association (WMA); Importance of the WMA principles.


Related Articles

  • Optimization of a DNA Vaccine Against SARS. Zakhartchouk, Alexander N.; Viswanathan, Sathiyanarayanan; Moshynskyy, Igor; Petric, Martin; Babiuk, Lorne A. // DNA & Cell Biology;Oct2007, Vol. 26 Issue 10, p721 

    Severe acute respiratory syndrome coronavirus (SARS-CoV) first appeared in Southern China in November 2002, and then quickly spread to 33 countries on five continents along international air travel routes. Although the SARS epidemic has been contained, there is a clear need for a safe and...

  • Promising SARS Vaccine. Hampton, Tracy // JAMA: Journal of the American Medical Association;8/25/2004, Vol. 292 Issue 8, p916 

    Reports on a promising nasal spray vaccine for SARS. How the experimental vaccine was designed by the National Institute of Allergy and Infectious Diseases; Belief the spray is ready for clinical trials; Evidence that the vaccine strain has been shown safe in children.

  • Neutralizing Antibodies in Patients with Severe Acute Respiratory Syndrome--Associated Coronavirus Infection. Yuchun Nie; Guangwen Wang; Xuanling Shi; Hong Zhang; Yan Qiu; Zhongping He; Wei Wang; Gewei Lian; Xiaolei Yin; Liying Du; Lili Ren; Jianwei Wang; Xiong He; Taisheng Li; Hongkui Deng; Mingxiao Ding // Journal of Infectious Diseases;9/15/2004, Vol. 190 Issue 6, p1119 

    Background. Severe acute respiratory syndrome (SARS)-associated coronavirus (SARS-CoV) is the principal etiologic agent of SARS. We analyzed serum samples obtained from 623 patients with SARS in Beijing, to determine whether infection with SARS-CoV can elicit neutralizing antibodies (NAbs)....

  • Neutralizing Antibody Response and SARS Severity. Mei-Shang Ho; Wei-Ju Chen; Hour-Young Chen; Szu-Fong Lin; Min-Chin Wang; Jiali Di; Yen-Ta Lu; Ching-Lu Liu; Shan-Chwen Chang; Chung-Liang Chao; Chwan-Chuen King; Jeng-Min Chiou; Ih-Jen Su; Jyh-Yuan Yang // Emerging Infectious Diseases;Nov2005, Vol. 11 Issue 11, p1730 

    Using the Taiwan nationwide laboratory-confirmed severe acute respiratory syndrome (SARS) database, we analyzed neutralizing antibody in relation to clinical outcomes. With a linear mixed model, neutralizing antibody titer was shown to peak between week 5 and week 8 after onset and to decline...

  • Evidence for Quasi Species in Severe Acute Respiratory Syndrome--Associated Coronavirus Deletion Mutants. Seligman, Stephen J. // Journal of Infectious Diseases;2/15/2007, Vol. 195 Issue 4, p609 

    A letter to the editor is presented in response to an article about the impact of an HIV-1 vaccine that reduces viral load set point after infection.

  • The structure of H5N1 avian influenza neuraminidase suggests new opportunities for drug design. Russell, Rupert J.; Haire, Lesley F.; Stevens, David J.; Collins, Patrick J.; Lin, Yi Pu; Blackburn, G. Michael; Hay, Alan J.; Gamblin, Steven J.; Skehel, John J. // Nature;9/7/2006, Vol. 443 Issue 7107, p45 

    The worldwide spread of H5N1 avian influenza has raised concerns that this virus might acquire the ability to pass readily among humans and cause a pandemic. Two anti-influenza drugs currently being used to treat infected patients are oseltamivir (Tamiflu) and zanamivir (Relenza), both of which...

  • Taiwanese scientists brace for second season of SARS. Yu-Tzu Chiu // Nature Medicine;Oct2003, Vol. 9 Issue 10, p1229 

    Reports that the Taiwanese government is strengthening its surveillance and research on SARS. Research efforts to develop a SARS vaccine; Testing of SARS-specific antibodies; Preparations for possible SARS outbreaks.

  • Smallpox and bioterrorism. Pennington, Hugh // Bulletin of the World Health Organization;2003, Vol. 81 Issue 10, p762 

    Smallpox was declared to be eradicated on 8 May 1980, during the Thirty-third World Health Assembly. However, concerns about the possible use of the virus as a weapon of bioterrorism have increased in recent years. Governments have responded by initiating selective vaccination programmes and...

  • The Global Response to SARS.  // UN Chronicle;Jun-Aug2003, Vol. 40 Issue 2, p11 

    Reports on the global response to severe acute respiratory syndrome initiated by the World Health Organization in the U.S. Absence of vaccine for the disease; Chain of transmission from infection infected to healthy persons; Lapses between onset of the illness and isolation of the patient.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics